ZTS Zoetis Inc

By Will Feuer

Zoetis Inc. has agreed to buy Basepaws, a privately held petcare-genetics company, to bolster Zoetis's portfolio in the precision animal-health space, the company said Tuesday.

Basepaws helps pet owners and veterinarians identify an individual pet's risk for disease through genetic testing and can lead to increased likelihood of early detection and treatment, Zoetis said.

The companies did not disclose the financial terms of the deal.

"With the addition of Basepaws, Zoetis will continue to strengthen our portfolio of products for precision animal health, across genetics, diagnostics and data analytics for pets and livestock," Abhay Nayak, Zoetis's executive vice president of strategy and commercial development, said.

"We are also excited by how Basepaws' feline genomic and microbiome database will help enhance our R&D capabilities and inform the future of our petcare pipeline," he added.

Write to Will Feuer at Will.Feuer@wsj.com

(END) Dow Jones Newswires

June 07, 2022 09:06 ET (13:06 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.